Universal Beteiligungs und Servicegesellschaft mbH Grows Position in The Clorox Company (NYSE:CLX)

Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of The Clorox Company (NYSE:CLX) by 35.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,261 shares of the company’s stock after buying an additional 35,228 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.11% of Clorox worth $19,623,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Redwood Park Advisors LLC purchased a new position in shares of Clorox in the 4th quarter worth approximately $26,000. Wood Tarver Financial Group LLC purchased a new position in shares of Clorox in the 4th quarter worth approximately $31,000. GKV Capital Management Co. Inc. purchased a new position in shares of Clorox in the 4th quarter worth approximately $32,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Clorox in the 4th quarter worth approximately $33,000. Finally, GW&K Investment Management LLC boosted its holdings in shares of Clorox by 239.1% in the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock worth $43,000 after purchasing an additional 208 shares during the period. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Up 1.3%

CLX opened at $131.44 on Thursday. The business’s 50-day simple moving average is $126.95 and its 200-day simple moving average is $140.67. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a one year low of $117.35 and a one year high of $171.37. The stock has a market capitalization of $16.20 billion, a P/E ratio of 23.60, a price-to-earnings-growth ratio of 3.41 and a beta of 0.51.

Clorox (NYSE:CLX) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.74 billion. During the same period in the prior year, the business earned $1.71 EPS. The business’s quarterly revenue was down 8.0% compared to the same quarter last year. Analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Insiders Place Their Bets

In other news, Director Pierre R. Breber purchased 4,000 shares of the firm’s stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the purchase, the director directly owned 4,000 shares of the company’s stock, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.57% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on CLX. Morgan Stanley decreased their target price on Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company reduced their price target on Clorox from $142.00 to $135.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 9th. Citigroup reissued a “neutral” rating and issued a $135.00 price target (down from $140.00) on shares of Clorox in a research report on Tuesday, July 15th. Jefferies Financial Group reduced their price target on Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. Finally, UBS Group reduced their price target on Clorox from $150.00 to $134.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $145.17.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.